143 related articles for article (PubMed ID: 10189480)
1. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling.
Sugawara Y; Zasadny KR; Grossman HB; Francis IR; Clarke MF; Wahl RL
Radiology; 1999 Apr; 211(1):249-56. PubMed ID: 10189480
[TBL] [Abstract][Full Text] [Related]
2. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
3. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients.
Stephens AW; Gonin R; Hutchins GD; Einhorn LH
J Clin Oncol; 1996 May; 14(5):1637-41. PubMed ID: 8622082
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
6. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
7. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies.
Torizuka T; Zasadny KR; Recker B; Wahl RL
Radiology; 1998 Jun; 207(3):767-74. PubMed ID: 9609902
[TBL] [Abstract][Full Text] [Related]
8. The role of positron emission tomography in germ cell cancer.
De Santis M; Pont J
World J Urol; 2004 Apr; 22(1):41-6. PubMed ID: 15024601
[TBL] [Abstract][Full Text] [Related]
9. Can nitrogen-13 ammonia kinetic modeling define myocardial viability independent of fluorine-18 fluorodeoxyglucose?
Beanlands RS; deKemp R; Scheffel A; Nahmias C; Garnett ES; Coates G; Johansen HL; Fallen E
J Am Coll Cardiol; 1997 Mar; 29(3):537-43. PubMed ID: 9060890
[TBL] [Abstract][Full Text] [Related]
10. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
Pfannenberg AC; Oechsle K; Bokemeyer C; Kollmannsberger C; Dohmen BM; Bares R; Hartmann JT; Vonthein R; Claussen CD
World J Urol; 2004 Jun; 22(2):132-9. PubMed ID: 14735310
[TBL] [Abstract][Full Text] [Related]
11. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose.
Heiss WD; Pawlik G; Herholz K; Wagner R; Göldner H; Wienhard K
J Cereb Blood Flow Metab; 1984 Jun; 4(2):212-23. PubMed ID: 6609929
[TBL] [Abstract][Full Text] [Related]
12. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
13. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.
Minn H; Lapela M; Klemi PJ; Grénman R; Leskinen S; Lindholm P; Bergman J; Eronen E; Haaparanta M; Joensuu H
J Nucl Med; 1997 Dec; 38(12):1907-11. PubMed ID: 9430467
[TBL] [Abstract][Full Text] [Related]
14. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
Johns Putra L; Lawrentschuk N; Ballok Z; Hannah A; Poon A; Tauro A; Davis ID; Hicks RJ; Bolton DM; Scott AM
Urology; 2004 Dec; 64(6):1202-7. PubMed ID: 15596197
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver.
Choi Y; Hawkins RA; Huang SC; Brunken RC; Hoh CK; Messa C; Nitzsche EU; Phelps ME; Schelbert HR
J Nucl Med; 1994 May; 35(5):818-23. PubMed ID: 8176464
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy.
Reinhardt MJ; Müller-Mattheis VG; Gerharz CD; Vosberg HR; Ackermann R; Müller-Gärtner HW
J Nucl Med; 1997 Jan; 38(1):99-101. PubMed ID: 8998160
[TBL] [Abstract][Full Text] [Related]
17. Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography.
Miyazawa H; Osmont A; Petit-Taboué MC; Tillet I; Travère JM; Young AR; Barré L; MacKenzie ET; Baron JC
J Neurosci Methods; 1993 Dec; 50(3):263-72. PubMed ID: 8152238
[TBL] [Abstract][Full Text] [Related]
18. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.
Sanchez D; Zudaire JJ; Fernandez JM; Lopez J; Arocena J; Sanz G; Gimenez M; Rosell D; Robles JE; Berian JM
BJU Int; 2002 Jun; 89(9):912-6. PubMed ID: 12010239
[TBL] [Abstract][Full Text] [Related]
19. Increased 18F-FDG uptake by a retroperitoneal mature cystic teratoma in an infant.
Suh YJ; Kim MJ; Lee MJ
Clin Nucl Med; 2014 Apr; 39(4):352-4. PubMed ID: 24300359
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor.
Kimura N; Yamamoto Y; Kameyama R; Hatakeyama T; Kawai N; Nishiyama Y
Nucl Med Commun; 2009 Aug; 30(8):602-9. PubMed ID: 19521265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
